North America Clostridium Botulinum Market

North America Clostridium Botulinum Market Size (2024 to 2029)

The size of the North America Clostridium Botulinum Market is forecasted to grow at a promising CAGR between 2024 to 2029. 

The availability of effective botulism therapies, increased awareness of disease and treatments, increasing R&D efforts, and the lack of sanitation in some areas of the world are all significant factors driving the growth of the Clostridium Botulinum market in North America. Furthermore, the illness is progressively being eradicated due to the WHO and the CDC's tireless efforts.

The Clostridium Botulinum market in North America is expanding due to population growth, the growing importance of minimally invasive or non-invasive procedures, and higher R&D spending. Rising botulism cases and improved awareness of the numerous dangerous bacteria are expected to boost the growth of the clostridium botulinum market. In addition, the increasing number of government programs supporting clinical healthcare R&D, as well as more advanced treatment facilities, are optimistic signals for market growth.

The rising number of epidemic diseases, rising healthcare expenditures, and key industry participants' interest in establishing research centers are all contributing to market expansion. For example, in 2016, Ipsen S.A. got FDA approval in the United States for its Dysport injectable, which is used to treat children aged two years and above for pediatric lower limb (PLL) and is also used in adults. As a result, in the United States, roughly 7.2 million botulinum injections were utilized for cosmetic operations in 2017. In addition, the growing number of cosmetic aesthetic procedures successfully enhanced market expansion during the forecast period. 

The expansion of the Clostridium Botulinum market in North America is expected to be hampered by high research and development expenditures and government austerity.

The World Health Organization has declared the coronavirus (COVID-19) a public health emergency (WHO). Governments imposed a nationwide shutdown with strict regulations to prevent the virus from spreading. All hospitals were advised to delay, cancel, or postpone any non-emergency medical treatments to recover medical capacity in COVID-19 patients. As a result of the epidemic, the clostridium botulinum market has suffered. Injections are recommended every 3 to 4 months for persons with this condition. A substantial number of people missed or canceled appointments due to their fear of the coronavirus.

This research report on the North America Clostridium botulinum market has been segmented and sub-segmented into the following categories.

By Product Type:

• Botulinum Toxin Type A      
• Botulinum Toxin Type B     

By Application:

• Aesthetics
• Therapeutics  

By Distribution Channel:

• Hospitals  
• Clinics        
• Retail pharmacies 

By Country:

• The United States
• Canada
• Rest of North America

Geographically, the North American regional market dominated the global market in 2020. Greater demand for aesthetic procedures increased research and development attempts to broaden botulinum toxin's therapeutic applications, and improved patient desire for non-invasive or minimally invasive treatments are contributing to the creation of innovative products. Botulinum toxin operations accounted for 46.1 percent of all non-invasive procedures performed in 2019, according to a 2019 survey by the International Society of Aesthetic Plastic Surgery. With 5,429,754 operations conducted in 2019, botulinum toxin was the most popular nonsurgical surgery among women 2019. Botulinum toxin operations were performed on nearly 841,735 men.

The US is likely to dominate the Clostridium Botulinum market in North America during the forecast period. According to current data from the American Society of Plastic Surgeons (ASPS), botulinum toxin Type A topped the list of the 2,630,832 cosmetic non-invasive operations performed in the United States in 2019. Botulinum toxin injections for wrinkle treatment are among the most prevalent cosmetic procedures performed worldwide. In addition, it is one of the most common entrance procedures for practitioners looking to add aesthetic therapies into their practice.

After the United States, Canada is predicted to have the most significant share of the Clostridium Botulinum market in North America. In addition, in April 2022, Aquavit Holdings LLC announced that it had received an exclusive license to register, sell, and commercialize botulinum toxin in Canada (DTX-021). As a result, these approvals and launches boosted the overall market's expansion, which is expected to continue during the forecast period.

KEY MARKET PLAYERS:

Some of the notable players operating in the North American clostridium botulinum infections market are XOMA Ltd., AlphaVax, Inc., Cangene Corporation, Morphotek, Inc., DynPort Vaccine Company LLC, Emergent BioSolutions, Inc., Molecular Targeting Technologies, Inc., and many others.